Focus keyword: iso 15189 hematology analyzer requirements
Theme: Regulation & Compliance
Accreditors do not walk in and inspect your analyzer—they walk in and demand proof about it, and the proof is where most labs fail.
ISO 15189 evaluates the entire medical laboratory, but the hematology analyzer is the piece assessors probe hardest. They will want documented verification that the instrument meets its manufacturer performance claims on your samples, that you run appropriate internal quality control and external proficiency testing, that you have validated any off-label use, and that maintenance and calibration records are complete and current. An analyzer can be excellent and still fail an assessment if the evidence trail is thin.
Analytical performance verification
For a 5-part CBC analyzer, verification means checking precision, accuracy, linearity and carryover on your own patient population—not copying the manufacturer’s numbers. Peer-reviewed protocols and real data beat theoretical conformance every time.
QC, proficiency testing and traceability
Assessors look for a coherent QC strategy: daily internal controls across every parameter, enrollment in an external quality-assessment scheme, and calibration traceable to reference materials. Document your target ranges, your rules for action on failure, and your retesting decisions.
Maintenance and competence
Evidence a maintenance schedule actually followed, staff competency assessments completed and signed, and a documented response to every service call or flagged result. The analyzer record is your whole story in one file.
For a practical example in this space, see the automatic hematology analyzer.
Explore the diagnostic reagent portfolio.
Explore the analyzer frequently asked questions.
As a next step, review the RunMei Health.
Why This Matters: Authoritative Context
Regulatory context is grounded in primary sources: the EU In Vitro Diagnostic Regulation 2017/746 (IVDR) defines the transition and classification duties the industry tracks, the U.S. FDA’s 510(k) and De Novo pathways govern US market access under 21 CFR Part 820, and ISO 15189 and ISO 13485 set the quality and laboratory-management benchmarks referenced throughout. For WHO Prequalification, the WHO In Vitro Diagnostics and Laboratory Technology programme publishes the specifications and performance requirements that prequalification assessments apply. Consulting these primary texts keeps a sourcing or validation decision honest and defensible.
